In PCOS, a hidden blood-vessel flaw appeared only when blood sugar rose — in lab-grown cells

Women with polycystic ovary syndrome (PCOS) face elevated cardiovascular risk, and the usual suspects — insulin resistance, weight, lipids — do not fully account for it. A study reported October 15, 2026 took a different route to the question: reprogram PCOS patients' cells into stem cells, grow them into the endothelial cells that line blood vessels, and stress them with glucose to see what breaks.

What broke when glucose rose?

Under high-glucose conditions, the PCOS-derived endothelial cells developed mitochondrial dysfunction alongside dysregulation of myeloperoxidase (MPO), an enzyme best known from immune cells. The reframing matters: the vascular risk in PCOS may stem partly from a stable, cell-intrinsic mitochondrial defect rather than only from the body's hormonal and metabolic environment — because reprogramming should have wiped away most acquired marks, yet the phenotype persisted. In the dish, inhibiting MPO functionally rescued the cells.

What are the limits of this evidence?

Considerable ones, and the authors name them: only three stem-cell lines per group, a clinical comparison cohort too small to split by PCOS subtype, an acute rather than chronic glucose challenge, and no direct measurement of intracellular MPO inside patients' own endothelial cells. About half of the study's PCOS cohort already had pre-diabetes, which shows how common the glucose trigger is — but a cell model that responds to a sugar spike is not proof of what happens across years of blood-vessel life.

What would this mean if it holds up?

Two testable ideas follow. First, early, assertive glucose control in PCOS might protect vessels before diabetes ever develops, because the vulnerability is unmasked by glucose itself. Second, the MPO–mitochondria axis gives drug researchers a concrete target to test. Neither idea is a treatment today; both now have a framework for proper trials.

Where the evidence stands

• Established: PCOS is associated with increased cardiovascular risk, and endothelial dysfunction is an early step in blood-vessel disease.
• Preliminary: In endothelial cells derived from PCOS patients' induced pluripotent stem cells, high glucose induced mitochondrial dysfunction and MPO dysregulation, and MPO inhibition rescued the cells in vitro (2026) — based on three cell lines per group.
• Absent: Confirmation in patients' own blood vessels, chronic-exposure models, and any clinical evidence that MPO-targeted treatment or earlier glucose control reduces cardiovascular events in PCOS.